Compare Bristol-Myers Squibb Co (BMY) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs First Citizens BancShares Inc — how do they compare? Bristol-Myers Squibb Co trades at $64.82 (market cap $130.12B), while First Citizens BancShares Inc trades at $2,270.44 (market cap $25.26B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.2× First Citizens BancShares Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | FCNCA | |
|---|---|---|
Market Cap | $130.12B | $25.26B |
Sector | Health | Sector/Thematic |
52-Week High | $65.89 | $2.27K |
52-Week Low | $42.60 | $1.64K |
Enterprise Value | $164.11B | — |
Dividend Yield | 3.96% | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMY trades at $64.65, up 1.63% with bullish technical signals and strong fundamentals. The stock shows robust profitability with 18.87% net margin and 46.7% ROE, supported by recent FDA approval for ZENBEXUS therapy and consistent earnings beats. Valuation remains reasonable with P/E of 14.03 and P/S of 2.65. Analyst consensus price target stands at $68.56 with 45% buy ratings.
BMY presents a compelling investment case with strong growth portfolio offsetting patent cliffs, though risks include legal challenges and debt levels. The stock's current valuation and recent positive developments suggest potential upside toward analyst targets, balanced by competitive pressures in the biopharma sector.
First Citizens BancShares (FCNCA) trades at $2,271.31, up 0.81% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with a 12.19 P/E ratio, 25.23% net income margin, and consistent earnings beats in recent quarters. Recent business developments include expansion of commercial lending operations and strategic real estate acquisitions, supporting growth initiatives.
FCNCA presents a mixed outlook with strong earnings performance and reasonable valuation offset by cautious analyst sentiment. While technical indicators suggest continued upside potential, the 81.82% hold rating from analysts indicates concerns about valuation and deposit risks. Key opportunities include expanding commercial banking services, while risks center on net interest margin pressure and elevated uninsured deposits at 38.3%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
